Century Therapeutics

IPSC · NASDAQ

$1.64+$0.17 (+11.56%)TodayMarket closed ·
Prev close $1.47

Key indicators

IPSC profitability and balance sheet ratios

EPS -$0.1679 in Q2 FY26, against -$0.3773 a year earlier.

EPS by quarter
PeriodEPS
Q3 FY24-$0.3686
Q4 FY24-$0.4223
Q1 FY25$0.8892
Q2 FY25-$0.3773
Q3 FY25-$0.3981
Q4 FY25-$0.2196
Q1 FY26-$0.1119
Q2 FY26-$0.1679

Where the money went

Q1 FY25, from revenue to net income

Century Therapeutics brought in $109.2M of revenue in Q1 FY25, +12667.7% on a year earlier. 70¢ of every dollar became profit.

Revenue
$109.2M
Costs, expenses and taxes
$32.6M
Net income
$76.6M
Net margin
70.1%

Income statement

Revenue and profit by reporting period

Revenue
Net income
IPSC income statement, quarterly
Line itemQ4 FY25Q1 FY26Q2 FY26
Revenue$0.0M$0.0M$0.0M
Gross profit$0.0M$0.0M$0.0M
Operating income−$20.7M−$23.7M−$36.5M
Net income−$19.2M−$21.6M−$34.6M
Diluted EPS-$0.22-$0.11-$0.17

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
IPSC balance sheet, quarterly
Line itemDec 2025Mar 2026Jun 2026
Total assets$223.7M$326.6M$287.0M
Total liabilities$64.8M$61.8M$54.7M
Shareholder equity$158.9M$264.7M$232.3M
Cash and short-term investments$117.1M$134.8M$119.7M
Total debt$0.0M$0.0M$0.0M

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
IPSC cash flow, quarterly
Line itemQ4 FY25Q1 FY26Q2 FY26
Operating cash flow−$16.1M−$25.3M−$19.8M
Investing cash flow$22.4M−$112.6M$17.8M
Financing cash flow$0.1M$126.6M$0.3M
Capital expenditure−$0.1M−$0.6M−$0.7M
Free cash flow−$16.2M−$25.8M−$20.5M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.